A.I. drug discovery platform Insilico Medicine announces $255 million in Series C funding
Companies, agencies, institutions, etc
Insilico Medicine
A.I
Crunchbase
Insilico Medicine’s
AI
FDA
IPF
Qiming Venture Partners
Pavilion Capital
Roads Ventures
Lilly Asia Ventures
Sinovation Ventures
BOLD Capital Partners
Formic Ventures
Baidu Ventures
CPE
OrbiMed
Mirae Asset Capital
B Capital Group
Deerfield Management
Maison Capital
Lake Bleu Capital
International Development Corporation
Sequoia Capital China
Sage Partners
Zhavoronkov
Deloitte
Nature Biotechnology
Pfizer
Taisho Pharmaceuticals
Teva Branded Pharmaceutical Products
Stanford University’s
Zhavorokov
People
Alex Zhavoronkov
Warburg Pincus
Insilco
Johnson
Groups
No matching tags
Physical locations
No matching tags
Places
No matching tags
Locations
Hong Kong
A.I
Events
AI superheroAlthough
Summary
The massive round is reflective of a recent breakthrough for the company: proof that it’s A.I based platform can create a new target for a disease, develop a bespoke molecule to address it, and begin the clinical trial process. Insilico Medicine is a Hong Kong-based company founded in 2014 around one central premise: that A.I assisted systems can identify novel drug targets for untreated diseases, assist in the development of new treatments, and eventually predict how well those treatments may perform in clinical trials. Insilico Medicine’s aim to use A.I to drive drug development isn’t particularly new, but there is some data to suggest that the company might actually accomplish that gauntlet of discovery all the way through trial prediction. The fact that we managed to do it in IPF and other diseases I can’t talk about yet – it increases confidence in A.I in general.” Bolstered partially by the proof-of-concept developed by the IPF project and enthusiasm around A.I based drug development, Insilico Medicine attracted a long list of investors in this most recent round.
As said here by Emma Betuel